Search company, investor...
Remedium Bio company logo

Remedium Bio

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$2.3M | 10 mos ago

About Remedium Bio

Remedium Bio is a Needham, Massachusetts-based gene therapy company focused on the development of treatments for a broad range of diseases.

Headquarters Location

1116 Great Plain Avenue

Needham, Massachusetts, 02492,

United States


Remedium Bio's Product Videos

Compete with Remedium Bio?

Ensure that your company and products are accurately represented on our platform.

Remedium Bio's Products & Differentiators

    RMD 1101

    First-in-class potentially disease modifying treatment for Osteoarthritis.

Expert Collections containing Remedium Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Remedium Bio is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Remedium Bio Patents

Remedium Bio has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Death
  • Medical aspects of death
patents chart

Application Date

Grant Date


Related Topics




Application Date


Grant Date


Related Topics



Latest Remedium Bio News

Biovian Oy. (3/16/23). "Press Release: Remedium Bio and Biovian Have Agreed to Collaborate on Remediums First-in-Class Disease M...

Mar 30, 2023

Product Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed on a collaboration for AAV drug development. The agreement covers Remedium’s lead candidate, a first-in-class disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification. Biovian has invented a robust way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing. Antti Nieminen, CEO at Biovian: "We are pleased to start a collaboration with Remedium Bio and to include Remedium’s AAV candidate in our ongoing second-generation AAV platform development program. Remedium’s therapeutic candidate will be important in the validation of Biovian’s second generation AAV platform – bringing a new level of quality and efficiency to the viral vector manufacturing space”. Frank Luppino, President and CEO at Remedium Bio: “Having recently generated one of the most comprehensive preclinical efficacy datasets in Osteoarthritis and presented at the 2023 Orthopedic Research Society meeting, we are extremely excited to scale production of our lead candidate RMD 1101 to support Toxicology and Clinical demand. Partnering with Biovian’s high-productivity viral vector manufacturing process will enable clinical supply and cost-effective production at eventual commercial scale for a disease that impacts hundreds of millions of people around the globe.” About Remedium Bio Remedium Bio, Inc., is a Boston area biotechnology company focused on the development of curative therapies for a broad range of pathologies. The company is founded on the vision of changing lives via curative breakthroughs, grounded in combining proven scientific fundamentals in novel ways, to treat well-characterized pathologies. Remedium’s current lead candidate is a disease-modifying treatment for Osteoarthritis that is based on the clinically validated mechanism of FGF18. Remedium’s scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues. Remedium’s pipeline includes gene therapy treatments in the fields of Rheumatology, Endocrinology, Neurology, and Immunology. Additional information is available at About Biovian Biovian is a Contract Development and Manufacturing Organization, CDMO that provides premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production and microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at Press Contact:

Remedium Bio Frequently Asked Questions (FAQ)

  • When was Remedium Bio founded?

    Remedium Bio was founded in 2020.

  • Where is Remedium Bio's headquarters?

    Remedium Bio's headquarters is located at 1116 Great Plain Avenue, Needham.

  • What is Remedium Bio's latest funding round?

    Remedium Bio's latest funding round is Seed VC.

  • How much did Remedium Bio raise?

    Remedium Bio raised a total of $3.67M.

  • Who are the investors of Remedium Bio?

    Investors of Remedium Bio include Sherwood Ventures, Angel Star Ventures, APIS Health Angels, Guindy Alumni Angels, MicroVentures Marketplace and 4 more.

  • Who are Remedium Bio's competitors?

    Competitors of Remedium Bio include Pacira Biosciences and 1 more.

  • What products does Remedium Bio offer?

    Remedium Bio's products include RMD 1101 and 3 more.

Compare Remedium Bio to Competitors


Lilly is a pharmaceutical company. The company focuses on diabetes, cancer, immunology, pain, and neurodegeneration drugs. It is based in Toronto, Ontario.


utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.

EZRA Innovations

EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.

Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

Critical Pharmaceuticals

Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.


Medipacs develops a non-mechanical infusion pump using a expandable polymer. TheMedipacs pump is designed to be wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost. The Medipacs novel polymer technology enables drug infusion pumps that are wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.